[1]
|
Malhotra, K., Shamkant, B.N., Chau, D.H., et al. (2016) Constraint Based Temporal Event Sequence Mining for Glioblastoma Survival Prediction. Journal of Biomedical Informatics, 61, 267-275.
http://dx.doi.org/10.1016/j.jbi.2016.03.020
|
[2]
|
Aliferis, C. and Trafalis, D.T. (2015) Glioblastoma Multiforme: Pathogenesis and Treatment. Pharmacology & Therapeutics, 152, 63-82. http://dx.doi.org/10.1016/j.pharmthera.2015.05.005
|
[3]
|
Stupp, R., Hegi, M.E., Gilbert, M.R. and Chakravarti, A. (2007) Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. Journal of Clinical Oncology, 25, 4127-4136. http://dx.doi.org/10.1200/JCO.2007.11.8554
|
[4]
|
Fouse, S.D., Nakamura, J.L., James, C.D., et al. (2014) Response of Primary Glioblastoma Cells to Therapy Is Patient Specific and Independent of Cancer Stem Cell Phenotype. Neuro-Oncology, 16, 361-371.
http://dx.doi.org/10.1093/neuonc/not223
|
[5]
|
Wherry, E.J. and Kurachi, M. (2015) Molecular and Cellular Insights into T Cell Exhaustion. Nature Reviews Immunology, 15, 486-499. http://dx.doi.org/10.1038/nri3862
|
[6]
|
Razavi, S.M., Lee, K.E., Jin, B.E., Aujla, P.S., Gholamin, S. and Li, G. (2016) Immune Evasion Strategies of Glioblastoma. Frontiers in Surgery, 3, 11. http://dx.doi.org/10.3389/fsurg.2016.00011
|
[7]
|
Topalian, S.L., Drake, C.G. and Pardoll, D.M. (2015) Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 27, 450-461. http://dx.doi.org/10.1016/j.ccell.2015.03.001
|
[8]
|
Yang, W., Bai, Y., Xiong, Y., et al. (2016) Potentiating the Antitumor Response of CD8+ T Cells by Modulating Cholesterol Metabolism. Nature, 531, 651-655. http://dx.doi.org/10.1038/nature17412
|
[9]
|
Snyder, A., Pamer, E. and Wolchok, J. (2015) Could Microbial Therapy Boost Cancer Immunotherapy? Science, 350, 1031-1032. http://dx.doi.org/10.1126/science.aad7706
|
[10]
|
Demeure, K., Fack, F., Duriez, E., et al. (2016) Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM). Molecular & Cellular Proteomics, 15, 481-492.
http://dx.doi.org/10.1074/mcp.M115.052423
|
[11]
|
Gzell, C.E., Wheeler, H.R., McCloud, P., Kastelan, M. and Back, M. (2016) Small Increases in Enhancement on MRI May Predict Survival Post Radiotherapy in Patients with Glioblastoma. Journal of Neuro-Oncology, 128, 67-74.
|
[12]
|
Li, Y., Du, Y., Liu, X., et al. (2015) Monitoring Tumor Targeting and Treatment Effects of IRDye 800CW and GX1-Conjugated Polylactic Acid Nanoparticles Encapsulating Endostar on Glioma by Optical Molecular Imaging. Molecular Imaging, 14, 356-365.
|
[13]
|
ClinicalTrials.gov, U.S. National Institutes of Health, Feb 2016.
|
[14]
|
Boessen, R., Heerspink, H.J.L., De Zeeuw, D., et al. (2014) Improving Clinical Trial Efficiency by Biomarker-Guided Patient Selection. Trials, 15, 103. http://dx.doi.org/10.1186/1745-6215-15-103
|
[15]
|
Barault, L., Amatu, A., Bleeker, F.E., et al. (2015) Digital PCR Quantification of MGMT Methylation Refines Prediction of Clinical Benefit from Alkylating Agents in Glioblastoma and Metastatic Colorectal Cancer. Annals of Oncology, 26, 1994-1999. http://dx.doi.org/10.1093/annonc/mdv272
|
[16]
|
Brigliadori, G., Foca, F., Dall’Agata, M., et al. (2016) Defining the Cutoff Value of MGMT Gene Promoter Methylation and Its Predictive Capacity in Glioblastoma. Journal of Neuro-Oncology, 128, 333-339.
http://dx.doi.org/10.1007/s11060-016-2116-y
|
[17]
|
Hegi, M.E., et al. (2005) MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. The New England Journal of Medicine, 352, 997-1003. http://dx.doi.org/10.1056/NEJMoa043331
|
[18]
|
Silber, J.R., Bobola, M.S., Blank, A. and Chamberlain, M.C. (2012) O6-Methylguanine-DNA Methyltransferase in Glioma Therapy: Promise and Problems. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1826, 71-82.
http://dx.doi.org/10.1016/j.bbcan.2011.12.004
|
[19]
|
D’Alessandris, Q.G., Montano, N., Cenci, T., et al. (2013) Targeted Therapy with Bevacizumab and Erlotinib Tailored to the Molecular Profile of Patients with Recurrent Glioblastoma. Preliminary Experience. Acta Neurochirurgica (Wien), 155, 33-40. http://dx.doi.org/10.1007/s00701-012-1536-5
|
[20]
|
Hegi, M.E., Diserens, A.C., Godard, S., et al. (2004) Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide. Clincal Cancer Research, 10, 1871-1874. http://dx.doi.org/10.1158/1078-0432.CCR-03-0384
|
[21]
|
Gutenberg, A., Bock, H.C., Bruck, W., et al. (2013) MGMT Promoter Methylation Status and Prognosis of Patients with Primary or Recurrent Glioblastoma Treated with Carmustine Wafers. British Journal of Neurosurgery, 27, 772-778. http://dx.doi.org/10.3109/02688697.2013.791664
|
[22]
|
Mellai, M., Caldera, V., Annovazzi, L., et al. (2009) MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas. Cancer Genomics Proteomics, 6, 219-227.
|
[23]
|
Minniti, G., Salvati, M., Arcella, A., et al. (2011) Correlation between O6-Methylguanine-DNA Methyltransferase and Survival in Elderly Patients with Glioblastoma Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide. Journal of Neuro-Oncology, 102, 311-316. http://dx.doi.org/10.1007/s11060-010-0324-4
|
[24]
|
Hegi, M.E. and Stupp, R. (2015) Withholding Temozolomide in Glioblastoma Patients with Unmethylated MGMT Promoter—Still a Dilemma? Neuro-Oncology, 17, 1425-1427. http://dx.doi.org/10.1093/neuonc/nov198
|
[25]
|
Parney, I.F., Chang, L.J., Farr-Jones, M.A., Hao, C.H., Smylie, M. and Petruk, K.C. (2006) Technical Hurdles in a Pilot Clinical Trial of Combined B7-2 and GM-CSF Immunogene Therapy for Glioblastomas and Melanomas. Journal of Neuro-Oncology, 78, 71-80. http://dx.doi.org/10.1007/s11060-005-9058-0
|
[26]
|
Shah, A., Bregy, A., Heros, D.O., Komotar, R.J. and Goldberg, J. (2013) Dendritic Cell Vaccine for Recurrent High-Grade Gliomas in Pediatric and Adult Subjects: Clinical Trial Protocol. Neurosurgery, 73, 863-867.
http://dx.doi.org/10.1227/NEU.0000000000000107
|
[27]
|
Ardon, H., Van Gool, S.W., Verschuere, T., et al. (2012) Integration of Autologous Dendritic Cell-Based Immunotherapy in the Standard of Care Treatment for Patients with Newly Diagnosed Glioblastoma: Results of the HGG-2006 Phase I/II Trial. Cancer Immunology, Immunotherapy, 61, 2033-2044. http://dx.doi.org/10.1007/s00262-012-1261-1
|
[28]
|
Ceschin, R., Kurland, B.F., Abberbock, S.R., Ellingson, B.M., Okada, H., et al. (2015) Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma. American Journal of Neuroradiology, 36, 2170-2176. http://dx.doi.org/10.3174/ajnr.A4428
|
[29]
|
Kebir, S., Fimmers, R., Galldiks, N., Schafer, N., Mack, F., et al. (2015) Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET. Clinical Cancer Research, 22, 2190-2196.
|
[30]
|
Thomas, A.A., Arevalo-Perez, J., Kaley, T., Lyo, J., Peck, K.K., et al. (2015) Dynamic Contrast Enhanced T1 MRI Perfusion Differentiates Pseudoprogression from Recurrent Glioblastoma. Journal of Neuro-Oncology, 125, 183-190.
http://dx.doi.org/10.1007/s11060-015-1893-z
|
[31]
|
Gahramanov, S., Varallyay, C., Tyson, R.M., Lacy, C., Fu, R., et al. (2014) Diagnosis of Pseudoprogression Using MRI Perfusion in Patients with Glioblastoma Multiforme May Predict Improved Survival. CNS Oncology, 3, 389-400.
http://dx.doi.org/10.2217/cns.14.42
|
[32]
|
Nasseri, M., Gahramanov, S., Netto, J.P., Fu, R., Muldoon, L.L., et al. (2014) Evaluation of Pseudoprogression in Patients with Glioblastoma Multiforme Using Dynamic Magnetic Resonance Imaging with Ferumoxytol Calls RANO Criteria into Question. Neuro-Oncology, 16, 1146-1154. http://dx.doi.org/10.1093/neuonc/not328
|
[33]
|
Macdonald, D.R., Cascino, T.L., Schold Jr., S.C. and Cairncross, J.G. (1990) Response Criteria for Phase II Studies of Supratentorial Malignant Glioma. Journal of Clinical Oncology, 8, 1277-1280.
|
[34]
|
Vogelbaum, M.A., Jost, S., Aghi, M.K., Heimberger, A.B., et al. (2012) Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery, 70, 234-243; discussion 243-244.
|
[35]
|
Lazovic, J., Jensen, M.C., Ferkassian, E., et al. (2008) Imaging Immune Response in Vivo: Cytolytic Action of Genetically Altered T Cells Directed to Glioblastoma Multiforme. Clinical Cancer Research, 14, 3832-3839.
http://dx.doi.org/10.1158/1078-0432.CCR-07-5067
|
[36]
|
Cohen, J.V., Alomari, A.K., Vortmeyer, A.O., Jilaveanu, L.B., Goldberg, S.B., et al. (2016) Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. Cancer Immunology Research, 4, 179-182.
http://dx.doi.org/10.1158/2326-6066.CIR-15-0160
|
[37]
|
Fabi, A., Russillo, M., Metro, G., Vidiri, A., Di Giovanni, S. and Cognetti, F. (2009) Pseudoprogression and MGMT Status in Glioblastoma Patients: Implications in Clinical Practice. Anticancer Research, 29, 2607-2610.
|
[38]
|
Hygino da Cruz, L.C., Rodriguez, I., Domingues, R.C., Gasparetto, E.L. and Sorensen, A.G. (2011) Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma. American Journal of Neuroradiology, 32, 1978-1985. http://dx.doi.org/10.3174/ajnr.A2397
|
[39]
|
Brandes, A.A., Fransceschi, E., Tosoni, A., et al. (2008) MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression after Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients. Journal of Clinical Oncology, 26, 2192-2197. http://dx.doi.org/10.1200/JCO.2007.14.8163
|
[40]
|
Reardon, D.A., Nabors, L.B., Mason, W.P., et al. (2015) Phase I/Randomized Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, with or without Protracted Temozolomide in Adults with Recurrent Glioblastoma. Neuro-Oncology, 17, 430-439.
|
[41]
|
Chauffert, B., Feuvret, L., Bonnetain, F., et al. (2014) Randomized Phase II Trial of Irinotecan and Bevacizumab as Neo-Adjuvant and Adjuvant to Temozolomide-Based Chemoradiation Compared with Temozolomide-Chemoradiation for Unresectable Glioblastoma: Final Results of the TEMAVIR Study from ANOCEF. Annals of Oncology, 25, 1442-1447. http://dx.doi.org/10.1093/annonc/mdu148
|
[42]
|
Han, S.J., Rolston, J.D., Molinaro, A.M., et al. (2014) Phase II Trial of 7 Days on/7 Days off Temozolomide for Recurrent High-Grade Glioma. Neuro-Oncology, 16, 1255-1262. http://dx.doi.org/10.1093/neuonc/nou044
|
[43]
|
Trippa, L., Wen, P.Y., Parmigiani, G., Berry, D.A. and Alexander, B.M. (2015) Combining Progression-Free Survival and Overall Survival as a Novel Composite Endpoint for Glioblastoma Trials. Neuro-Oncology, 17, 1106-1113.
http://dx.doi.org/10.1093/neuonc/nou345
|
[44]
|
Karsy, M., Neil, J.A., Guan, J., et al. (2015) A Practical Review of Prognostic Correlations of Molecular Biomarkers in Glioblastoma. Neurosurgical Focus, 38, E4. http://dx.doi.org/10.3171/2015.1.FOCUS14755
|
[45]
|
Chen, J.R., Yao, Y., Xu, H.Z. and Qin, Z.-Y. (2016) Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients with Glioblastomas. Medicine (Baltimore), 95, e2583.
http://dx.doi.org/10.1097/MD.0000000000002583
|
[46]
|
Montgomery, R.M., Queiroz, L.S. and Rogerio, F. (2015) EGFR, p53, IDH-1, and MDM2 Immunohistochemical Analysis in Glioblastoma: Therapeutic and Prognostic Correlation. Arquivos de Neuro-Psiquiatria, 73, 561-568.
http://dx.doi.org/10.1590/0004-282X20150059
|
[47]
|
Amelot, A., De Cremoux, P., Quillien, V., et al. (2015) IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. PLoS ONE, 10, e0130596. http://dx.doi.org/10.1371/journal.pone.0130596
|
[48]
|
Labussiere, M., Boisselier, B., Mokhtari, K., et al. (2014) Combined Analysis of TERT, EGFR, and IDH Status Defines Distinct Prognostic Glioblastoma Classes. Neurology, 83, 1200-1206.
http://dx.doi.org/10.1212/WNL.0000000000000814
|
[49]
|
Nencha, U., Rahimian, A., Giry, M., et al. (2016) TERT Promoter Mutations and rs2853669 Polymorphism: Prognostic Impact and Interactions with Common Alterations in Glioblastoma. Journal of Neuro-Oncology, 126, 441-446.
http://dx.doi.org/10.1007/s11060-015-1999-3
|
[50]
|
Leonard, B., Starrett, G.J., Maurer, M.J., et al. (2016) APOBEC3G Expression Correlates with T Cell Infiltration and Improved Clinical Outcomes in High-Grade Serous Ovarian Carcinoma. Clinical Cancer Research. (Epub Ahead of Print) http://dx.doi.org/10.1158/1078-0432.CCR-15-2910
|
[51]
|
Cescon, D.W., Haibe-Kains, B. and Mak, T.W. (2015) APOBEC3B Expression in Breast Cancer Reflects Cellular Proliferation, while a Deletion Polymorphism Is Associated with Immune Activation. Proceedings of the National Academy of Sciences of the United States of America, 112, 2841-2846. http://dx.doi.org/10.1073/pnas.1424869112
|
[52]
|
Hamakawa, T., Kukita, Y., Kurokawa, Y., et al. (2015) Monitoring Gastric Cancer Progression with Circulating Tumour DNA. British Journal of Cancer, 112, 352-356. http://dx.doi.org/10.1038/bjc.2014.609
|
[53]
|
Schwarzenbach, H., Alix-Panabieres, C., Muller, I., et al. (2009) Cell-Free Tumor DNA in Blood Plasma as a Marker for Circulating Tumor Cells in Prostate Cancer. Clinical Cancer Research, 15, 1032-1038.
http://dx.doi.org/10.1158/1078-0432.CCR-08-1910
|
[54]
|
Schwarzenbach, H., Muller, V., Milde-Langosch, K., Steinbach, B. and Pantel, K. (2011) Evaluation of Cell-Free Tumor DNA and RNA in Patients with Breast Cancer and Benign Breast Disease. Molecular BioSystems, 7, 2848-2854.
http://dx.doi.org/10.1039/c1mb05197k
|
[55]
|
Luo, H., Li, H., Wu, H., et al. (2016) Noninvasive Diagnosis and Monitoring of Mutations by Deep Sequencing of Circulating Tumor DNA in Esophageal Squamous Cell Carcinoma. Biochemical and Biophysical Research Communications, 471, 596-602. http://dx.doi.org/10.1016/j.bbrc.2016.02.011
|
[56]
|
Xu, S., Lou, F., Wu, Y., et al. (2016) Circulating Tumor DNA Identified by Targeted Sequencing in Advanced-Stage Non-Small Cell Lung Cancer Patients. Cancer Letters, 370, 324-331. http://dx.doi.org/10.1016/j.canlet.2015.11.005
|
[57]
|
Dawson, S.J., Tsui, D.W., Murtaza, M., et al. (2013) Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. The New England Journal of Medicine, 368, 1199-1209. http://dx.doi.org/10.1056/NEJMoa1213261
|
[58]
|
Lipson, E.J., Velculescu, V.E., Pritchard, T.S., et al. (2014) Circulating Tumor DNA Analysis as a Real-Time Method for Monitoring Tumor Burden in Melanoma Patients Undergoing Treatment with Immune Checkpoint Blockade. Journal for ImmunoTherapy of Cancer, 2, 42. http://dx.doi.org/10.1186/s40425-014-0042-0
|
[59]
|
Tie, J., Kinde, I., Wang, Y., et al. (2015) Circulating Tumor DNA as an Early Marker of Therapeutic Response in Patients with Metastatic Colorectal Cancer. Annals of Oncology, 26, 1715-1722.
http://dx.doi.org/10.1093/annonc/mdv177
|
[60]
|
Ocana, A., Diez-Gonzalez, L., Garcia-Olmo, D.C., et al. (2016) Circulating DNA and Survival in Solid Tumors. Cancer Epidemiology, Biomarkers & Prevention, 25, 399-406. http://dx.doi.org/10.1158/1055-9965.EPI-15-0893
|
[61]
|
Bidard, F.C., Madic, J., Mariani, P., et al. (2014) Detection Rate and Prognostic Value of Circulating Tumor Cells and Circulating Tumor DNA in Metastatic Uveal Melanoma. International Journal of Cancer, 134, 1207-1213.
http://dx.doi.org/10.1002/ijc.28436
|
[62]
|
Madic, J., Kiialainen, A., Bidard, F.C., et al. (2015) Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Triple Negative Breast Cancer Patients. International Journal of Cancer, 136, 2158-2165.
http://dx.doi.org/10.1002/ijc.29265
|
[63]
|
Westphal, M. and Lamszus, K. (2015) Circulating Biomarkers for Gliomas. Nature Reviews Neurology, 11, 556-566.
http://dx.doi.org/10.1038/nrneurol.2015.171
|
[64]
|
Herman, A., Gruden, K., Blejec, A., et al. (2015) Analysis of Glioblastoma Patients’ Plasma Revealed the Presence of MicroRNAs with a Prognostic Impact on Survival and Those of Viral Origin. PLoS ONE, 10, e0125791.
http://dx.doi.org/10.1371/journal.pone.0125791
|
[65]
|
Yan, J., Kong, L.Y., Hu, J., et al. (2015) FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. JNCI Journal of the National Cancer Institute, 107, djv137.
http://dx.doi.org/10.1093/jnci/djv137
|
[66]
|
Erdbruegger, U., Dhaygude, A., Haubiz, M. and Woywodt, A. (2010) Circulating Endothelial Cells: Markers and Mediators of Vascular Damage. Current Stem Cell Research & Therapy, 5, 294-302.
http://dx.doi.org/10.2174/157488810793351721
|
[67]
|
Batchelor, T.T., Sorensen, A.G., di Tomaso, E., et al. (2007) AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer Cell, 11, 83-95.
http://dx.doi.org/10.1016/j.ccr.2006.11.021
|
[68]
|
Yong, W.H., Shabihkhani, M., Telesca, D., et al. (2015) Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. PLoS ONE, 10, e0141334. http://dx.doi.org/10.1371/journal.pone.0141334
|
[69]
|
Sayour, E.J., McLendon, P., McLendon, R., et al. (2015) Increased Proportion of FoxP3+ Regulatory T Cells in Tumor Infiltrating Lymphocytes Is Associated with Tumor Recurrence and Reduced Survival in Patients in GBM. Cancer Immunology, Immunotherapy, 64, 419-427. http://dx.doi.org/10.1007/s00262-014-1651-7
|
[70]
|
Thomas, A.A., Fisher, J.L., Rahme, G.J., et al. (2015) Regulatory T Cells Are Not a Strong Predictor of Survival for Patients with GBM. Neuro-Oncology, 17, 801-809. http://dx.doi.org/10.1093/neuonc/nou363
|
[71]
|
Gray, E.S., Rizos, H., Reid, A.L., et al. (2015) Circulating Tumor DNA to Monitor Treatment Response and Detect Acquired Resistance in Patients with Metastatic Melanoma. Oncotarget, 6, 42008-42018.
|
[72]
|
Warton, K., Mahon, K.L. and Samimi, G. (2016) Methylated Circulating Tumor DNA in Blood: Power in Cancer Prognosis and Response. Endocrine-Related Cancer, 23, R157-R171. http://dx.doi.org/10.1530/ERC-15-0369
|
[73]
|
Shah, K., Boghozian, R.A., Kartsonaki, C., et al. (2016) YH2AX Expression in Cytological Specimens as a Biomarker of Response to Radiotherapy in Solid Malignancies. Diagnostic Cytopathology, 44, 141-146.
http://dx.doi.org/10.1002/dc.23396
|
[74]
|
Hooper, C.E., Lyburn, I.D., Searle, J., et al. (2015) The South West Area Mesothelioma and Pemetrexed Trial: A Multicenter Prospective Observational Study Evaluating Novel Markers of Chemotherapy Response and Prognostication. British Journal of Cancer, 112, 1175-1182. http://dx.doi.org/10.1038/bjc.2015.62
|
[75]
|
Mitchell, P.J., Welton, J., Staffurth, J., et al. (2009) Can Urinary Exosomes Act as Treatment Response Markers in Prostate Cancer? Journal of Translational Medicine, 7, 4. http://dx.doi.org/10.1186/1479-5876-7-4
|
[76]
|
Harder, J., Kummer, O., Olschewski, M., Otto, F., Blum, H.E. and Opitz, O. (2007) Prognostic Relevance of Carbohydrate Antigen 19-9 Levels in Patients with Advanced Biliary Tract Cancer. Cancer Epidemiology, Biomarkers & Prevention, 16, 2097-2100. http://dx.doi.org/10.1158/1055-9965.EPI-07-0155
|
[77]
|
Everson, R.G., Jin, R.M., Wang, X., et al. (2014) Cytokine Responsiveness of CD8+ T Cells Is a Reproducible Biomarker for the Clinical Efficacy of Dendritic Cell Vaccination in Glioblastoma Patients. Journal for ImmunoTherapy of Cancer, 2, 10. http://dx.doi.org/10.1186/2051-1426-2-10
|
[78]
|
Muller, L., Muller-Haegele, S., Mitsuhashi, M., et al. (2015) Exosomes Isolated from Plasma of Glioma Patients Enrolled in a Vaccination Trial Reflect Antitumor Immune Activity and Might Predict Survival. OncoImmunology, 4, e1008347. http://dx.doi.org/10.1080/2162402X.2015.1008347
|
[79]
|
Chen, H.Y., Li, X.Y., Li, W.B. and Zheng, H.Y. (2015) MiR-130a Can Predict Response to Temozolomide in Patients with Glioblastoma Multiforme, Independently of O6-Methylguanine-DNA Methyltransferance. Journal of Translational Medicine, 13, 69. http://dx.doi.org/10.1186/s12967-015-0435-y
|
[80]
|
Comimelli, M., Grisanti, S., Mazzoleni, S., et al. (2015) EGFR Amplified and Overexpressing Glioblastomas and Associations with Better Response to Adjuvant Metronomic Temozolomide. JNCI Journal of the National Cancer Institute, 107, djv041.
|
[81]
|
Lamano, J.B., Ampie, L., Choy, W., et al. (2016) Immunomonitoring in Glioma Immunotherapy: Current Status and Future Perspectives. Journal of Neuro-Oncology, 127, 1-13. http://dx.doi.org/10.1007/s11060-015-2018-4
|
[82]
|
Mazmanian, S.K., Round, J.L. and Kasper, D.L. (2008) A Microbial Symbiosis Factor Prevents Intestinal Inflammatory Disease. Nature, 453, 620-625. http://dx.doi.org/10.1038/nature07008
|
[83]
|
Cash, H.L. (2006) Symbiotic Bacteria Direct Expression of an Intestinal Bactericidal Lectin. Science, 313, 1126-1130.
http://dx.doi.org/10.1126/science.1127119
|
[84]
|
Berman, D., Parker, S.M., Siegel, J., Chasalow, S.D., Weber, J., et al. (2010) Blockade of Cytotoxic T-Lymphocyte Antigen-4 by Ipilimumab Results in Dysregulation of Gastrointestinal Immunity in Patients with Advanced Melanoma. Cancer Immunity, 10, 11.
|
[85]
|
Vetizou, M., Pitt, J.M., Daillere, R., et al. (2015) Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota. Science, 350, 1079-1084. http://dx.doi.org/10.1126/science.aad1329
|
[86]
|
Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., et al. (2015) Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy. Science, 350, 1084-1089.
http://dx.doi.org/10.1126/science.aac4255
|
[87]
|
Linhares, P., Carvalho, B., Figueiredo, R., Reis, R.M. and Vaz, R. (2013) Early Pseudoprogression Following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation. Journal of Oncology, 2013, Article ID: 690585. http://dx.doi.org/10.1155/2013/690585
|
[88]
|
Bulik, M., Kazda, T., Slampa, P. and Jancalek, R. (2015) The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectoscopy and Apparent Diffusion Coefficient Mapping. BioMed Research International, 2015, Article ID: 641023.
http://dx.doi.org/10.1155/2015/641023
|
[89]
|
Kelm, Z.S., Korfiatis, P.D., Lingineni, R.K., et al. (2015) Variability and Accuracy of Different Software Packages for Dynamic Susceptibility Contrast Magnetic Resonance Imaging for Distinguishing Glioblastoma Progression from Pseudoprogression. Journal of Medical Imaging, 2, 026001. http://dx.doi.org/10.1117/1.JMI.2.2.026001
|
[90]
|
Galldiks, N., Dunkl, V., Stoffels, G., et al. (2015) Diagnosis of Pseudoprogression in Patients with Glioblastoma Using O-(2-[18F]fluoroethyl)-L-tyrosine PET. European Journal of Nuclear Medicine and Molecular Imaging, 42, 685-695.
http://dx.doi.org/10.1007/s00259-014-2959-4
|
[91]
|
Cha, J., Kim, S.T., Kim, H.J., et al. (2014) Differentiation of Tumor Progression from Pseudoprogression in Patients with Posttreatment Glioblastoma Using Multiparametric Histogram Analysis. American Journal of Neuroradiology, 35, 1309-1317. http://dx.doi.org/10.3174/ajnr.A3876
|
[92]
|
Park, J.E., Kim, H.S., Goh, M.J., Kim, S.J. and Kim, J.H. (2015) Pseudoprogression in Patients with Glioblastoma: Assessment by Using Volume-Weighted Voxel-Based Multiparametric Clustering of MR Imaging Data in an Independent Test Set. Radiology, 275, 792-802. http://dx.doi.org/10.1148/radiol.14141414
|
[93]
|
Suh, C.H., Kim, H.S., Choi, Y.J., Kim, N. and Kim, S.J. (2013) Prediction of Pseudoprogression in Patients with Glioblastomas Using the Initial and Final Area under the Curves Ratio Derived from Dynamic Contrast-Enhanced T1-Weighted Perfusion MR Imaging. American Journal of Neuroradiology, 34, 2278-2286.
http://dx.doi.org/10.3174/ajnr.A3634
|
[94]
|
Song, Y.S., Choi, S.H., Park, C.K., et al. (2013) True Progression versus Pseudoprogression in the Treatment of Glioblastomas: A Comparison Study of Normalized Cerebral Blood Volume and Apparent Diffusion Coefficient by Histogram Analysis. Korean Journal of Radiology, 14, 662-672. http://dx.doi.org/10.3348/kjr.2013.14.4.662
|
[95]
|
Gahramanov, S., Muldoon, L.L., Varallyay, C.G., et al. (2013) Pseudoprogression of Glioblastoma after Chemo- and Radiation Therapy: Diagnosis by Using Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging with Ferumoxytol versus Gadoteridol and Correlation with Survival. Radiology, 266, 842-852.
http://dx.doi.org/10.1148/radiol.12111472
|
[96]
|
Chu, H.H., Choi, S.H., Ryoo, I., et al. (2013) Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Radiation Therapy and Concomitant Temozolomide: Comparison Study of Standard and High-b-Value Diffusion-Weighted Imaging. Radiology, 269, 831-840. http://dx.doi.org/10.1148/radiol.13122024
|
[97]
|
Laymon, C.M., Oborski, M.J., Lee, V.K., et al. (2012) Combined Imaging Biomarkers for Therapy Evaluation in Glioblastoma Multiforme: Correlating Sodium MRI and F-18 FLT PET on a Voxel-Wise Basis. Magnetic Resonance Imaging, 30, 1268-1278. http://dx.doi.org/10.1016/j.mri.2012.05.011
|
[98]
|
Cairncross, J.G., Wang, M., Jenkins, R.B., et al. (2014) Benefit from Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated with Mutation of IDH. Journal of Clinical Oncology, 32, 783-790.
http://dx.doi.org/10.1200/JCO.2013.49.3726
|
[99]
|
Balmanoukian, A., Ye, X., Herman, J., Laheru, D. and Grossman, S.A. (2012) The Association between Treatment-Related Lymphopenia and Survival in Newly Diagnosed Patients with Resected Adenocarcinoma of the Pancreas. Cancer Investigation, 30, 571-576. http://dx.doi.org/10.3109/07357907.2012.700987
|
[100]
|
Grossman, S.A., Ellsworth, S., Campian, J., et al. (2015) Survival in Patients with Severe Lymphopenia Following Treatment with Radiation and Chemotherapy for Newly Diagnosed Solid Tumors. Journal of the National Comprehensive Cancer Network, 13, 1225-1231.
|
[101]
|
Ellsworth, S., Balmanoukian, A., Kos, F., et al. (2014) Sustained CD4+ T Cell-Driven Lymphopenia without a Compensatory IL-7/IL-15 Response among High-Grade Glioma Patients Treated with Radiation and Temozolomide. OncoImmunology, 3, e27357. http://dx.doi.org/10.4161/onci.27357
|
[102]
|
Wen, P.Y., Cloughesy, T.F., Ellingson, B.M., et al. (2014) Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA Clinical Trials Neuroimaging Endpoint Workshop. Neuro-Oncology, 16, 36-47.
http://dx.doi.org/10.1093/neuonc/nou226
|
[103]
|
Floeth, F.W., Wittsack, H.J., Engelbrecht, V. and Weber, F. (2002) Comparative Follow-Up of Enhancement Phenomena with MRI and Proton MR Spectroscopic Imaging after Intralesional Immunotherapy in Glioblastoma—Report of Two Exceptional Cases. Zentralbl Neurochir, 63, 23-28. http://dx.doi.org/10.1055/s-2002-31579
|
[104]
|
Yang, I., Huh, N.G., Smith, Z.A., et al. (2010) Distinguishing Glioma Recurrence from Treatment Effect after Radiochemotherapy and Immunotherapy. Neurosurgery Clinics of North America, 21, 181-186.
http://dx.doi.org/10.1016/j.nec.2009.08.003
|
[105]
|
Reardon, D.A., Akabani, G., Coleman, R.E., et al. (2002) Phase II Trial of murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered into Surgically Created Resection Cavities of Patients with Newly Diagnosed Malignant Gliomas. Journal of Clinical Oncology, 20, 1389-1397. http://dx.doi.org/10.1200/JCO.20.5.1389
|
[106]
|
Tran, E., Ahmadzadeh, M., Lu, Y.C., et al. (2015) Immunogenicity of Somatic Mutations in Human Gastrointestinal Cancers. Science, 350, 1387-1390. http://dx.doi.org/10.1126/science.aad1253
|
[107]
|
Chan, T.A., Wolchok, J.D. and Snyder, A. (2015) Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. The New England Journal of Medicine, 373, 1984. http://dx.doi.org/10.1056/NEJMc1508163
|